5vyf: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
==Structure of single chain Fel d 1 bound to a neutralizing antibody== | ==Structure of single chain Fel d 1 bound to a neutralizing antibody== | ||
<StructureSection load='5vyf' size='340' side='right' caption='[[5vyf]], [[Resolution|resolution]] 2.90Å' scene=''> | <StructureSection load='5vyf' size='340' side='right'caption='[[5vyf]], [[Resolution|resolution]] 2.90Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[5vyf]] is a 6 chain structure with sequence from [ | <table><tr><td colspan='2'>[[5vyf]] is a 6 chain structure with sequence from [https://en.wikipedia.org/wiki/Felis_catus Felis catus] and [https://en.wikipedia.org/wiki/Mus_musculus Mus musculus]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5VYF OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=5VYF FirstGlance]. <br> | ||
</td></tr><tr id=' | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.9Å</td></tr> | ||
<tr id=' | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=CA:CALCIUM+ION'>CA</scene></td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[ | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=5vyf FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5vyf OCA], [https://pdbe.org/5vyf PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=5vyf RCSB], [https://www.ebi.ac.uk/pdbsum/5vyf PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=5vyf ProSAT]</span></td></tr> | ||
</table> | </table> | ||
== Function == | |||
[https://www.uniprot.org/uniprot/FEL1B_FELCA FEL1B_FELCA] [https://www.uniprot.org/uniprot/FEL1A_FELCA FEL1A_FELCA] | |||
<div style="background-color:#fffaf0;"> | <div style="background-color:#fffaf0;"> | ||
== Publication Abstract from PubMed == | == Publication Abstract from PubMed == | ||
| Line 17: | Line 19: | ||
</div> | </div> | ||
<div class="pdbe-citations 5vyf" style="background-color:#fffaf0;"></div> | <div class="pdbe-citations 5vyf" style="background-color:#fffaf0;"></div> | ||
==See Also== | |||
*[[Fel d 1|Fel d 1]] | |||
*[[Monoclonal Antibodies 3D structures|Monoclonal Antibodies 3D structures]] | |||
== References == | == References == | ||
<references/> | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: | [[Category: Felis catus]] | ||
[[Category: | [[Category: Large Structures]] | ||
[[Category: | [[Category: Mus musculus]] | ||
[[Category: | [[Category: Franklin MC]] | ||
Latest revision as of 17:02, 4 October 2023
Structure of single chain Fel d 1 bound to a neutralizing antibodyStructure of single chain Fel d 1 bound to a neutralizing antibody
Structural highlights
FunctionPublication Abstract from PubMedAcute allergic symptoms are caused by allergen-induced crosslinking of allergen-specific immunoglobulin E (IgE) bound to Fc-epsilon receptors on effector cells. Desensitization with allergen-specific immunotherapy (SIT) has been used for over a century, but the dominant protective mechanism remains unclear. One consistent observation is increased allergen-specific IgG, thought to competitively block allergen binding to IgE. Here we show that the blocking potency of the IgG response to Cat-SIT is heterogeneous. Next, using two potent, pre-selected allergen-blocking monoclonal IgG antibodies against the immunodominant cat allergen Fel d 1, we demonstrate that increasing the IgG/IgE ratio reduces the allergic response in mice and in cat-allergic patients: a single dose of blocking IgG reduces clinical symptoms in response to nasal provocation (ANCOVA, p = 0.0003), with a magnitude observed at day 8 similar to that reported with years of conventional SIT. This study suggests that simply augmenting the blocking IgG/IgE ratio may reverse allergy. Treating cat allergy with monoclonal IgG antibodies that bind allergen and prevent IgE engagement.,Orengo JM, Radin AR, Kamat V, Badithe A, Ben LH, Bennett BL, Zhong S, Birchard D, Limnander A, Rafique A, Bautista J, Kostic A, Newell D, Duan X, Franklin MC, Olson W, Huang T, Gandhi NA, Lipsich L, Stahl N, Papadopoulos NJ, Murphy AJ, Yancopoulos GD Nat Commun. 2018 Apr 12;9(1):1421. doi: 10.1038/s41467-018-03636-8. PMID:29650949[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
| ||||||||||||||||||